SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors react to multiple adverse court rulings involving youth safety and addictive platform design. The stock's sharp decline has sparked intense debate on community boards, with some users highlighting the potential for widespread litigation risks while others dismiss the sell-off as an overreaction and a long-term buying opportunity for a strong cash-generating business.

Implementing a basic decaying neuron activation model simulating the spiking behavior of a biological worm's nervous system that creates movement, and putting it on-chain  With some caveats, this is Worm - immortal digital life  The Worm will vastly outlive you or I, with the exception of global catastrophe, it is immortal digital life that inherits the resilience and decentralization of the solana network  If the underlying blockchain exists, the 'life' of The Worm will persist indefinitely

Deep Worm

The community is actively discussing a migration from WORM to NEMA, highlighting the transition toward autonomous neural simulation technology and decentralized digital organisms. Market participants are focused on the integration with protocol-level infrastructure and the launch of interactive digital pets as key drivers for renewed interest in the ecosystem.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors scrutinize the company's aggressive capital expenditures in AI and recent hiring freezes within its cloud division. The community remains deeply divided, with some traders highlighting the stock's extreme oversold status as a generational buying opportunity, while others express frustration over its persistent downward trend compared to other mega-cap tech stocks.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

NextDecade is trending as investors weigh significant insider buying and strategic interest against recent volatility, with the community closely tracking potential project expansion and its role in the global energy supply landscape. Discussions are dominated by the stocks technical setup and long-term valuation potential amid ongoing geopolitical dynamics affecting global LNG demand.

Tower Semiconductor Ltd. engages in providing semiconductor solutions. It also offers technology and manufacturing platforms for integrated circuits (ICs) in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical, and aerospace and defense. It focuses on creating positive and sustainable impact on the world through long term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, integrated power management (BCD and 700V), and MEMS. Its designs enable a quick and accurate design cycle as well as process transfer services including development, transfer, and optimization, to IDMs and fabless companies. The company was founded in 1993 and is headquartered in Migdal Haemek, Israel.

Tower Semiconductor Ltd.

Tower Semiconductor is currently trending as investors closely monitor the outcome of its pending acquisition by Intel, with market sentiment wavering amid regulatory uncertainty and speculation regarding a potential termination fee. The community remains divided, weighing the stock's long-term potential in the high-demand semiconductor and silicon photonics space against the risks of a deal collapse and recent price volatility.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is experiencing significant volatility as investors digest a contentious short report alleging channel stuffing, a claim the company has moved to refute while citing inaccurate and misleading assertions. Community sentiment is deeply divided, with many long-term holders treating the sharp price decline as a buying opportunity while others express frustration over management's perceived lack of urgency in addressing the allegations.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is seeing significant trading activity as investors pivot to the symbol as an alternative proxy for SpaceX and Anthropic exposure, largely driven by comparisons to the valuation premiums seen in VCX. Community discussion is heavily focused on the potential impact of an upcoming SpaceX IPO and the stock's relative valuation compared to its net asset value, with many participants actively debating whether this represents an undervalued entry point for institutional-grade private tech holdings.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as investors focus on its role in real-world asset (RWA) tokenization, fueled by major institutional partnerships like Franklin Templeton and expanding operations on the Solana blockchain. While some in the community express frustration over price volatility and upcoming token unlocks, others remain bullish on its long-term potential to bridge traditional finance with decentralized infrastructure.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community chatter as traders react to ongoing price volatility and high-volume accumulation ahead of the anticipated Goliath mainnet launch. Investors remain sharply divided, with bulls pointing to potential institutional infrastructure and staking rewards, while bears express concern over the lack of verifiable partnerships and historical patterns of selling pressure.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is currently trending as investors weigh strong defense sector tailwinds and potential contract wins against broader market volatility and institutional profit-taking. The community is actively debating the company's long-term growth as a rugged Edge AI player, with many shareholders maintaining conviction in holding through near-term consolidation despite recent price fluctuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure without added toxicity in metastatic breast cancer patients.read more...

<ul class="summary-bullets"><li>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company announced that it is building an AI data center for Anthropic.</li><li>Processa Pharmaceuticals' shares were up nearly 95% after early Phase 2 data showed that its NGC-Cap therapy boosts capecitabine exposure without added side effects compared with standard treatment.</li><li>Recursion Pharmaceuticals shares jumped over 16% by midday Wednesday after Morgan Stanley upgraded the stock to ‘Overweight’ and raised its price target to $11, citing strong efficacy for its drug REC-4881.</li></ul>U.S. equities were in the red in Wednesday’s midday trade as investors exercised caution amid a broader decline in artificial intelligence stocks, with Oracle and Broadcom shares declining by nearly 5% each.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.68% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, declined 1.28%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, fell 0.2%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Wednesday’s midday trade:</h2><a href="https://stocktwits.com/symbol/ORCL">Oracle Corp. (ORCL)</a>Oracle shares were down over 5% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-s-ai-expansion-hits-snag-as-key-investor-pulls-back-report/cLeO1HSREqa">faced</a> a setback in its AI data center expansion efforts after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.<a href="https://stocktwits.com/symbol/ORCL">ORCL stock</a> is up 8% year-to-date.<a href="https://stocktwits.com/symbol/HUT">Hut 8 Corp. (HUT)</a>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hut-shares-soar-over-24-percet-today-whats-the-deal-involving-google-and-anthropic/cLeO1aZREqJ">announced</a> that it is building an AI data center for Anthropic, and that it had signed a 15-year, $7 billion lease with Fluidstack. The company added that the lease would be worth up to $17.7 billion if all renewal options are exercised.<a href="https://stocktwits.com/symbol/HUT">HUT stock</a> is up 100% year-to-date.<a href="https://stocktwits.com/symbol/PCSA">Processa Pharmaceuticals Inc. (PCSA)</a>Processa Pharmaceuticals share price nearly doubled, hovering at gains of 95% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-processa-pharmaceuticals-stock-surge-160-today/cLeOVJlREqV">stated</a> that its early Phase 2 trial data showed that its NGC-Cap therapy significantly increases exposure to capecitabine cancer-killing drug metabolites without increasing the severity of side effects compared to standard monotherapy capecitabine therapy.<a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> is down 73% year-to-date.<a href="https://stocktwits.com/symbol/RXRX">Recursion Pharmaceuticals Inc. (RXRX)</a>Recursion Pharmaceuticals shares were up over 16% in Wednesday’s midday session after Morgan Stanley upgraded the stock to ‘Overweight’ from ‘Neutral’, according to TheFly. The firm also hiked its price target for the RXRX stock to $11 from $10, citing “strong and durable” efficacy in familial adenomatous polyposis from the company's small-molecule drug, REC-4881.<a href="https://stocktwits.com/symbol/RXRX">RXRX stock</a> is down 28% year-to-date.<a href="https://stocktwits.com/symbol/UDMY">Udemy Inc. (UDMY)</a>Udemy shares were up more than 22% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cour-udmy-stock-premarket-coursera-udemy-announce-merger/cLeOKUtREq4">announced</a> a merger with Coursera Inc. (COUR), with an implied equity value of the combined entity of approximately $2.5 billion.<a href="https://stocktwits.com/symbol/UDMY">UDMY stock</a> is down 20% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/waller-fed-chair-odds-surge-after-dovish-comments/cLeOjlBREqg">Waller's Odds For Fed Chair Nomination Surge After The Fed Governor's Dovish Comments On Rate Cuts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today

Oracle shares were down over 5% in Wednesday’s midday session after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.

Equity

<ul class="summary-bullets"><li>Processa plans to complete enrollment for the formal 20-patient interim analysis by the end of the first quarter of 2026.</li><li>The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday.</li><li>Trading in PCSA shares was halted multiple times today, according to Nasdaq data.</li></ul>Processa Pharmaceuticals Inc. (PCSA) surged over 160% on Wednesday, after the company announced that early Phase 2 data showed that its Next Generation Cancer (NGC) therapy delivered higher levels of cancer-fighting metabolites in patients with advanced or metastatic breast cancer.The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday. Trading in <a href="https://stocktwits.com/symbol/PCSA">PCSA shares</a> was halted multiple times on Wednesday, according to Nasdaq data.<h2 class="st-heading-2">Phase 2 Study Results&nbsp;</h2>Preliminary data from the first 16 of 19 enrolled patients indicated that NGC-Cap significantly increases exposure to capecitabine’s cancer-killing metabolites compared with standard capecitabine monotherapy without increasing the severity of side effects seen with standard treatment. The company believes the balance could improve outcomes for patients with advanced breast cancer.Nineteen patients were randomized to receive either NGC-Cap (150 mg twice daily) or standard Mono-Cap (1,000 mg/m² twice daily). Early safety data from the first 16 patients show higher exposure to cancer-killing metabolites in the NGC-Cap group.While more patients in the NGC-Cap group experienced side effects related to these metabolites, the severity was similar to that in the Mono-Cap group.&nbsp;Processa plans to complete enrollment for the formal 20-patient interim analysis, which will include both safety and efficacy data, by the end of the first quarter of 2026. The company expects to report the interim analysis in early 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’, amid ‘extremely high’ message volumes. PCSA was the top trending ticker on Stocktwits.<figure class="image"><img style="aspect-ratio:922/93;" src="https://news.stocktwits-cdn.com/PCSA_png_df422e4216.webp" alt="PCSA.png" width="922" height="93"><figcaption>PCSA's Sentiment Meter and Message Volumes at 11:30 a.m. ET on Dec. 17, 2025 | Source: Stocktwits</figcaption></figure>One Stocktwits user expects further upside to the stock.<stembedurl>https://stocktwits.com/AJWW316/message/639440673</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/uwm-holdings-to-acquire-two-harbors-investment-in-1-3-b-deal/cLeOjLYREqf">UWM Holdings To Acquire Two Harbors Investment In $1.3B Deal - How Much Of The Combined Company Will UWM Shareholders Own?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Why Did Processa Pharmaceuticals Stock Surge 160% Today?

The company announced that early Phase 2 data showed that its NGC therapy increased cancer-fighting metabolites in patients with advanced breast cancer.

$PCSA Q4 &#39;25 Earnings Results &amp; Recap

Processa Pharmaceuticals Inc. reported a net loss of $13.6M for the year ended December 31, 2025, with $11.4M in net cash used in operating activities and $5.5M in cash and cash equivalents.

Stocktwits

Processa Pharmaceuticals Inc

 Q4 '25 Earnings Results & Recap

Processa Pharmaceuticals Inc. reported a net loss of $13.6M for the year ended December 31, 2025, with $11.4M in net cash used in operating activities and $5.5M in cash and cash equivalents.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

Current Price	$2.24
Prev Close	$2.30
Open	$2.29
Dividend Yield	0.00%
50-Day Moving Average	$2.65
Beta	0.94
Avg. Volume	49,391.12
PE Ratio	-0.13

52-Week High	$19.63
52-Week Low	$1.76
Market Capitalization	$5.96M
EPS (Annual)	-$10.36
Price to Book	1.03
Revenue Per Employee	$0.00

PCSA
Processa Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PCSA News

PCSAProcessa Pharmaceuticals Inc